Ivabradine induces RAD51 degradation, potentiating PARP inhibitor efficacy in non-germline BRCA pathogenic variant triple-negative breast cancer
This study highlights the translational potential of repurposing ivabradine as a therapeutic strategy for non-gBRCAm TNBC. By addressing a critical unmet need of this aggressive breast cancer subtype, it can potentially expand the utility of PARPi.
Authors
- Ka Man Cheung (ORCID: https://orcid.org/0000-0002-8476-0239)
- Ho Tsoi (ORCID: https://orcid.org/0000-0003-2037-9575)
- G. Leung (ORCID: https://orcid.org/0009-0002-7878-4741)
- US Khoo (ORCID: https://orcid.org/0000-0003-2200-7505)
- Kelvin Y.K. Chan (ORCID: https://orcid.org/0000-0002-5272-0005)
- Chun Gong (ORCID: https://orcid.org/0000-0002-2298-937X)
- Michael Shing Yan Huen
- Ellen P.S. Man
- Chan Ping You
Institutions
- University of Cambridge (GB)
- HKU-Pasteur Research Pole (HK)
- University of Hong Kong (HK)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-08-05
- DOI
- https://doi.org/10.1186/s12967-025-06902-8
- Citations
- 2
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Research Grants Council, University Grants Committee
- Innovation and Technology Commission
- University Research Committee, University of Hong Kong
- Health and Medical Research Fund